Ionis Pharmaceuticals (IONS)

$63.16 -0.88 (-1.37%)
Market Cap 10.20B
Revenue (ttm) 705.14M
Net Income (ttm) -453.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -64.37%
Debt to Equity Ratio 0.09
Volume 1,471,400
Avg Vol 2,549,098
Day's Range N/A - N/A
Shares Out 159.39M
Stochastic %K 97%
Beta 0.28
Analysts Strong Sell
Price Target $67.26

Company Profile

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treat...

Industry: Biotechnology
Sector: Healthcare
Phone: 760 931 9200
Address:
2855 Gazelle Court, Carlsbad, United States
Joe_Mama
Joe_Mama Sep. 11 at 11:36 PM
$IONS Quietly kicking a$$. Top target $86! Congrats to loyal Bulls here. I’ve been long since this was ISIS! Who’s with me?
0 · Reply
johnnygogogo
johnnygogogo Sep. 11 at 12:35 PM
$IONS knows and just acknowledged that Tryngolza is inferior to Plozasiran (REDEMPLO) through their cowardly legal threats. Scared of real competition and view tactics like these as their only chance to keep market share. $ARWR / CA publicly exposing it and taking the high road once again, and at the same time solidifying support of the FCS community. I would be embarrassed to own IONS. https://stocks.apple.com/A2wUjQC0FQcOSpIpWiSsccQ
2 · Reply
Rikster
Rikster Sep. 11 at 12:18 PM
$IONS
0 · Reply
ZacksResearch
ZacksResearch Sep. 10 at 4:22 PM
$IONS just got a major boost 🚀 FDA granted Breakthrough Therapy status to ION582 for Angelman syndrome, and the drug is already in phase III trials. Full story here 👉 https://www.zacks.com/stock/news/2749509/ions-up-on-fdas-breakthrough-tag-for-ion582-in-angelman-syndrome?cid=sm-stocktwits-2-2749509-teaser-11806&ADID=SYND_STOCKTWITS_TWEET_2_2749509_TEASER_11806
0 · Reply
ZacksResearch
ZacksResearch Sep. 10 at 3:22 PM
$IONS soars 5.6% on FDA breakthrough nod for ION582! 🚀 The designation, driven by promising phase I/II results, could accelerate the development and review process for treating Angelman syndrome, a rare neurological disorder. Year to date, Ionis shares have surged 84.2%, outpacing the industry’s 12.5% rise. Discover the full story here 👉 https://www.zacks.com/stock/news/2749509/ions-up-on-fdas-breakthrough-tag-for-ion582-in-angelman-syndrome?cid=sm-stocktwits-2-2749509-body-11793&ADID=SYND_STOCKTWITS_TWEET_2_2749509_BODY_11793
0 · Reply
highnihilism
highnihilism Sep. 10 at 2:42 PM
$IONS Ionis Pharmaceuticals hit a 52-week high on FDA Breakthrough Therapy status for its Angelman drug, plus analyst upgrades. Insiders sold a little into the rally. #ETSY Etsy’s platform engagement & merchant growth are reinforcing the $72 level. Consumer-spending resilience (whimsigoth, fetish fashion, nostalgia, handmade crafts, domestic charm, heritage demand). #SG Sweetgreen’s luxury athleisure lifestyle setting: bright & clean interior, crisp greens, bright wooden textures (post-class vibe) is reinforcing the $18 level. Where energized femininity resonates. #XHB Homebuilder demand trends & housing supply dynamics are reinforcing the $120 level. Fed rate-cut speculation & “golden cross” approaching. #BTC Bitcoin’s on-chain metrics & institutional flows are propping up the $114,000 level. Fed rate-cut speculation & “liquidity expansion.”
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Sep. 9 at 5:52 PM
$IONS Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status
0 · Reply
Bankpas
Bankpas Sep. 9 at 11:09 AM
$IONS Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome September 9, 2025
0 · Reply
Lard_ass_piggy
Lard_ass_piggy Sep. 5 at 4:54 PM
$IONS 100$ mega pump
0 · Reply
CaptiolGainsSociety
CaptiolGainsSociety Sep. 5 at 3:32 PM
$IONS insider trading! Pump and dump. Get out while you can
2 · Reply
Latest News on IONS
Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases

Sep 12, 2025, 7:00 AM EDT - 13 hours ago

Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases

Ionis: Recent Approvals, Upcoming Catalysts To Spur Strong Upside (Rating Upgrade)

Sep 11, 2025, 2:14 AM EDT - 1 day ago

Ionis: Recent Approvals, Upcoming Catalysts To Spur Strong Upside (Rating Upgrade)

Ionis Pharmaceuticals, Inc. (IONS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 6:11 PM EDT - 3 days ago

Ionis Pharmaceuticals, Inc. (IONS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status

Sep 9, 2025, 1:51 PM EDT - 3 days ago

Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status

Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome

Sep 9, 2025, 7:00 AM EDT - 3 days ago

Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome

Ionis Pharmaceuticals, Inc. (IONS) Presents At H.C. Wainwright 27th Annual Global Investment Conference (Transcript)

Sep 8, 2025, 5:33 PM EDT - 4 days ago

Ionis Pharmaceuticals, Inc. (IONS) Presents At H.C. Wainwright 27th Annual Global Investment Conference (Transcript)

Ionis to host investors and analysts for Innovation Day 2025

Sep 8, 2025, 4:00 PM EDT - 4 days ago

Ionis to host investors and analysts for Innovation Day 2025

Ionis Pharmaceuticals, Inc. (IONS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 4, 2025, 1:47 PM EDT - 8 days ago

Ionis Pharmaceuticals, Inc. (IONS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Is The 35% Rally In IONS Stock Just The Beginning?

Sep 3, 2025, 10:41 AM EDT - 9 days ago

Is The 35% Rally In IONS Stock Just The Beginning?

Ionis to present at upcoming investor conferences

Sep 2, 2025, 4:00 PM EDT - 10 days ago

Ionis to present at upcoming investor conferences

Ionis Pharmaceuticals, Inc. (IONS) Positive CORE And CORE2 Topline Results (Transcript)

Sep 2, 2025, 12:26 PM EDT - 10 days ago

Ionis Pharmaceuticals, Inc. (IONS) Positive CORE And CORE2 Topline Results (Transcript)

Ionis Pharmaceuticals stock rockets 31% to new 52-week high on breakthrough news

Sep 2, 2025, 11:17 AM EDT - 10 days ago

Ionis Pharmaceuticals stock rockets 31% to new 52-week high on breakthrough news

Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction

Sep 2, 2025, 10:38 AM EDT - 10 days ago

Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction

Ionis shares jump after drug lowers blood fat levels in advanced trials

Sep 2, 2025, 9:25 AM EDT - 10 days ago

Ionis shares jump after drug lowers blood fat levels in advanced trials

Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)

Sep 2, 2025, 7:00 AM EDT - 10 days ago

Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)

mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 15 days ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX DHR GRAL ILMN MRNA RGEN

Ionis: Dawnzera Approval Kicks Off New Era For Strikingly Undervalued Pharma

Aug 26, 2025, 3:50 PM EDT - 17 days ago

Ionis: Dawnzera Approval Kicks Off New Era For Strikingly Undervalued Pharma

US FDA approves Ionis' drug for rare genetic disorder

Aug 21, 2025, 11:58 AM EDT - 22 days ago

US FDA approves Ionis' drug for rare genetic disorder

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

Aug 21, 2025, 11:45 AM EDT - 22 days ago

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

Ionis Pharmaceuticals, Inc. (IONS) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 4:42 PM EDT - 6 weeks ago

Ionis Pharmaceuticals, Inc. (IONS) Q2 2025 Earnings Call Transcript

Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug

Jul 30, 2025, 2:34 PM EDT - 6 weeks ago

Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug

Ionis reports second quarter 2025 financial results and highlights progress on key programs

Jul 30, 2025, 7:00 AM EDT - 6 weeks ago

Ionis reports second quarter 2025 financial results and highlights progress on key programs

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)

Jul 25, 2025, 7:15 AM EDT - 7 weeks ago

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)

Ionis Pharmaceuticals founder Stanley Crooke on the fight against rare diseases

Jul 23, 2025, 7:41 AM EDT - 7 weeks ago

Ionis Pharmaceuticals founder Stanley Crooke on the fight against rare diseases

Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice

Jul 21, 2025, 7:00 AM EDT - 7 weeks ago

Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice

Ionis to hold second quarter 2025 financial results webcast

Jul 16, 2025, 7:05 AM EDT - 2 months ago

Ionis to hold second quarter 2025 financial results webcast

Ionis: After Years Of Investment, The Wholly-Owned Payoff Is In Sight

Jun 29, 2025, 1:04 PM EDT - 2 months ago

Ionis: After Years Of Investment, The Wholly-Owned Payoff Is In Sight

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results

Jun 25, 2025, 7:31 AM EDT - 2 months ago

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results

Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026

Jun 12, 2025, 9:00 AM EDT - 3 months ago

Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

Jun 11, 2025, 7:00 AM EDT - 3 months ago

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides

May 19, 2025, 7:00 AM EDT - 4 months ago

Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides

Ionis to host 2025 virtual Annual Meeting of Stockholders

May 6, 2025, 7:05 AM EDT - 4 months ago

Ionis to host 2025 virtual Annual Meeting of Stockholders

Ionis Pharmaceuticals, Inc. (IONS) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 2:20 PM EDT - 4 months ago

Ionis Pharmaceuticals, Inc. (IONS) Q1 2025 Earnings Call Transcript

Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge

Apr 30, 2025, 2:05 PM EDT - 4 months ago

Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge

Ionis reports first quarter 2025 financial results

Apr 30, 2025, 7:00 AM EDT - 4 months ago

Ionis reports first quarter 2025 financial results

New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies

Apr 29, 2025, 7:00 AM EDT - 4 months ago

New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies

Ionis: Potentially A Great Time To Buy Ahead Of Q1 Earnings (Upgrade)

Apr 22, 2025, 2:12 PM EDT - 5 months ago

Ionis: Potentially A Great Time To Buy Ahead Of Q1 Earnings (Upgrade)

Ionis to host expert panel discussion on sHTG

Apr 3, 2025, 7:05 AM EDT - 5 months ago

Ionis to host expert panel discussion on sHTG

Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.

Mar 26, 2025, 7:00 AM EDT - 6 months ago

Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.

Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera

Mar 11, 2025, 6:00 PM EDT - 6 months ago

Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera

Ionis and Ono announce global license agreement for sapablursen in polycythemia vera

Mar 11, 2025, 6:00 PM EDT - 6 months ago

Ionis and Ono announce global license agreement for sapablursen in polycythemia vera

WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy

Mar 10, 2025, 7:00 AM EDT - 6 months ago

WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy

New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control

Feb 20, 2025, 7:00 AM EST - 7 months ago

New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control

Ionis Pharmaceuticals, Inc. (IONS) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 4:10 PM EST - 7 months ago

Ionis Pharmaceuticals, Inc. (IONS) Q4 2024 Earnings Call Transcript

Ionis Pharmaceuticals Reports Strong Q4 Earnings After Recent FDA Approval

Feb 19, 2025, 2:40 PM EST - 7 months ago

Ionis Pharmaceuticals Reports Strong Q4 Earnings After Recent FDA Approval

Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales

Feb 19, 2025, 12:11 PM EST - 7 months ago

Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales

Ionis reports fourth quarter and full year 2024 financial results

Feb 19, 2025, 7:00 AM EST - 7 months ago

Ionis reports fourth quarter and full year 2024 financial results

Ionis to hold fourth quarter and full year 2024 financial results webcast

Feb 5, 2025, 7:05 AM EST - 7 months ago

Ionis to hold fourth quarter and full year 2024 financial results webcast

Amyloidosis Treatment Market Research by Treatment, Drug Class, End-User, and Region - Global Forecasts to 2034

Jan 15, 2025, 9:17 AM EST - 8 months ago

Amyloidosis Treatment Market Research by Treatment, Drug Class, End-User, and Region - Global Forecasts to 2034

Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum

Jan 13, 2025, 8:00 AM EST - 8 months ago

Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum

Joe_Mama
Joe_Mama Sep. 11 at 11:36 PM
$IONS Quietly kicking a$$. Top target $86! Congrats to loyal Bulls here. I’ve been long since this was ISIS! Who’s with me?
0 · Reply
johnnygogogo
johnnygogogo Sep. 11 at 12:35 PM
$IONS knows and just acknowledged that Tryngolza is inferior to Plozasiran (REDEMPLO) through their cowardly legal threats. Scared of real competition and view tactics like these as their only chance to keep market share. $ARWR / CA publicly exposing it and taking the high road once again, and at the same time solidifying support of the FCS community. I would be embarrassed to own IONS. https://stocks.apple.com/A2wUjQC0FQcOSpIpWiSsccQ
2 · Reply
Rikster
Rikster Sep. 11 at 12:18 PM
$IONS
0 · Reply
ZacksResearch
ZacksResearch Sep. 10 at 4:22 PM
$IONS just got a major boost 🚀 FDA granted Breakthrough Therapy status to ION582 for Angelman syndrome, and the drug is already in phase III trials. Full story here 👉 https://www.zacks.com/stock/news/2749509/ions-up-on-fdas-breakthrough-tag-for-ion582-in-angelman-syndrome?cid=sm-stocktwits-2-2749509-teaser-11806&ADID=SYND_STOCKTWITS_TWEET_2_2749509_TEASER_11806
0 · Reply
ZacksResearch
ZacksResearch Sep. 10 at 3:22 PM
$IONS soars 5.6% on FDA breakthrough nod for ION582! 🚀 The designation, driven by promising phase I/II results, could accelerate the development and review process for treating Angelman syndrome, a rare neurological disorder. Year to date, Ionis shares have surged 84.2%, outpacing the industry’s 12.5% rise. Discover the full story here 👉 https://www.zacks.com/stock/news/2749509/ions-up-on-fdas-breakthrough-tag-for-ion582-in-angelman-syndrome?cid=sm-stocktwits-2-2749509-body-11793&ADID=SYND_STOCKTWITS_TWEET_2_2749509_BODY_11793
0 · Reply
highnihilism
highnihilism Sep. 10 at 2:42 PM
$IONS Ionis Pharmaceuticals hit a 52-week high on FDA Breakthrough Therapy status for its Angelman drug, plus analyst upgrades. Insiders sold a little into the rally. #ETSY Etsy’s platform engagement & merchant growth are reinforcing the $72 level. Consumer-spending resilience (whimsigoth, fetish fashion, nostalgia, handmade crafts, domestic charm, heritage demand). #SG Sweetgreen’s luxury athleisure lifestyle setting: bright & clean interior, crisp greens, bright wooden textures (post-class vibe) is reinforcing the $18 level. Where energized femininity resonates. #XHB Homebuilder demand trends & housing supply dynamics are reinforcing the $120 level. Fed rate-cut speculation & “golden cross” approaching. #BTC Bitcoin’s on-chain metrics & institutional flows are propping up the $114,000 level. Fed rate-cut speculation & “liquidity expansion.”
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Sep. 9 at 5:52 PM
$IONS Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status
0 · Reply
Bankpas
Bankpas Sep. 9 at 11:09 AM
$IONS Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome September 9, 2025
0 · Reply
Lard_ass_piggy
Lard_ass_piggy Sep. 5 at 4:54 PM
$IONS 100$ mega pump
0 · Reply
CaptiolGainsSociety
CaptiolGainsSociety Sep. 5 at 3:32 PM
$IONS insider trading! Pump and dump. Get out while you can
2 · Reply
SmartMoneyTradez
SmartMoneyTradez Sep. 5 at 2:30 PM
$IONS Going up but insiders dumping heavy. Short candidate
3 · Reply
CaptiolGainsSociety
CaptiolGainsSociety Sep. 5 at 1:52 PM
$IONS I’m in Puts for October 17 contracts. I would buy between 42.5-$45 put for maximum profit. RSI 82
2 · Reply
IN0V8
IN0V8 Sep. 4 at 3:37 PM
$IONS Buy BMO raises target price to $70.00 from $40.00 BMO raises to outperform from market perform BofA Global Research raises price objective to $69 from $64 Citigroup raises target price to $84 from $69 Morgan Stanley raises target price to $71.00 from $62.00 Needham raises target price to $70 from $55
1 · Reply
victorgn
victorgn Sep. 3 at 7:24 PM
$IONS late breakout ??
0 · Reply
JPtheBCRXdestroyer1
JPtheBCRXdestroyer1 Sep. 3 at 6:51 PM
$IONS delayed reaction to Dawnzera approval. Maybe the market is pricing a big thank you note for taking down the scammers running $BCRX for them.
2 · Reply
victorgn
victorgn Sep. 3 at 6:19 PM
$IONS the run starts now..
0 · Reply
JarvisFlow
JarvisFlow Sep. 3 at 4:32 PM
Citigroup has adjusted their stance on Ionis Pharmaceuticals ( $IONS ), setting the rating to Buy with a target price of 69 → 84.
0 · Reply
ZacksResearch
ZacksResearch Sep. 3 at 3:52 PM
🔥 $IONS surges 35% on positive results for Tryngolza in sHTG treatment! 📊 Tryngolza delivered up to 72% triglyceride reductions and cut acute pancreatitis risk by 85% in late-stage studies. With a market significantly larger than FCS, the blockbuster potential is huge! Discover the full story 👉 https://www.zacks.com/stock/news/2746745/ions-hits-52-week-high-on-tryngolzas-success-in-lowering-triglyceride?cid=sm-stocktwits-2-2746745-body-10748&ADID=SYND_STOCKTWITS_TWEET_2_2746745_BODY_10748
0 · Reply
onefryshy
onefryshy Sep. 3 at 3:10 PM
$IONS Goldman Sachs maintains a cell on iona's pharmaceutical raises the price Target to $45 from 40. Talk about a group that has no idea what's going on.
0 · Reply
anachartanalyst
anachartanalyst Sep. 3 at 3:02 PM
$IONS https://anachart.com/wp-content/uploads/ana_temp/1756911719_soc-img.jpg
0 · Reply
Quantumup
Quantumup Sep. 3 at 3:01 PM
H.C. Wainwright reiterated $ARWR Buy/$80. $IONS $ETNB $NVS $AZN ALNY REGN H.C. Wainwright said:
0 · Reply
ZacksResearch
ZacksResearch Sep. 3 at 2:48 PM
$IONS breaking out to a 52-week high 🚀 The move comes on the back of Tryngolza’s success in lowering triglyceride levels — a key milestone driving momentum. Discover the full story here 👉 https://www.zacks.com/stock/news/2746745/ions-hits-52-week-high-on-tryngolzas-success-in-lowering-triglyceride?cid=sm-stocktwits-2-2746745-teaser-10731&ADID=SYND_STOCKTWITS_TWEET_2_2746745_TEASER_10731
0 · Reply